Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Price, Quote & News

Company Profile

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queens...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 980 4182

Website: quoinpharma.com

Address:

42127 Pleasant Forest Court, Ashburn, United States

TestacularTommy Jul. 17 at 12:06 AM

$QNRX worst 7k i ever spent, down 99%, my average is $6900🤣 what a joke,from all the R/S, thought monkey pox was going to keep this alive, what a scam, people use to defend this company, iremember the dsy it shot up like 1000% ,igot smoked, been a bagger since, shuld i just sell for $7K loss this year, or try to atleast get 1k back lol idnt think its possible

0 · Reply

Trust121 Jul. 14 at 6:45 PM

$QNRX Nice uptrend, steady

0 · Reply

Thestocktraderhubzee Jul. 9 at 9:30 AM

WATCHLIST JUL 09 2025 $ASH Ashland To Close Two New Jersey Plants In $60M Manufacturing Optimization Plan, Shifting Production To Larger Sites $ATR Aptar Unveils Dual-Active Material Science Technology To Protect Sensitive Pharma And Medical Devices From Moisture And Oxygen $QNRX On July 3, 2025, Quoin Pharmaceuticals And CFO Gordon Dunn Agreed To A Mutual Separation Later This Year; Mr. Dunn Will Continue In His Current Role Until His Successor Is Appointed $AGCO AGCO Corporation And TAFE Enter Fourth Amendment To Agreement; Amendment Extends Expiration Date To November 28, 2025 $TKO Esports World Cup Foundation Taps TKO-Owned IMG To Launch 'EWC Spotlight,' Merging Competitive Gaming, Entertainment And Global Broadcast Innovation

1 · Reply

StayPresent Jul. 8 at 2:02 AM

$QNRX pos

1 · Reply

TwongStocks Jul. 7 at 10:20 PM

$QNRX Preliminary proxy filed for shareholder meeting on Aug 21st. https://www.sec.gov/ix?doc=/Archives/edgar/data/1671502/000110465925066171/tm252555-1_pre14a.htm Proposals: 1) Election of Directors 2) Approve an increase in authorized share capital from 100m to 5B. 3) Approve the Compensation Policy for Executive Officers & Directors 4) Approve the 2025 Equity Incentive Plan 5) Approve changes to the non-employee directors’ compensation program 6) Approve options grants to certain non-employee directors 7) Appoint CBIZ CPAs PC as the company's registered independent auditor

0 · Reply

GreenResearchers Jul. 7 at 4:01 AM

Good luck traders I like the stocks tagged and keep an eye on SSY , small caps are HOT SSY is a textbook low-float sleeper with a catalyst. No dilution. Micro float. Merger with Regional Health is still in motion and the market’s ignoring it. These are the types of plays that go from dead quiet to 300%+ in a blink. You either see it early or chase it late. $GNS $IFBD $TIRX $QNRX

0 · Reply

GreenResearchers Jul. 5 at 8:31 PM

SSY is being slept on. Tiny float. No dilution. Under $1. There’s a major merger in the works and barely anyone’s watching. When these setups move, they don’t walk they rip. The chart is coiled, and all it needs is volume. $IFBD $QNRX $APRN $VEEE

0 · Reply

rockytoday Jul. 3 at 4:39 PM

$QNRX buy the dip

0 · Reply

magic2007 Jul. 3 at 2:23 PM

$QNRX So I invested 7k way back, and now I see I have 14 shares. Wow, I guess I ride it out..

1 · Reply

Kevin73ca Jun. 26 at 5:34 PM

$QNRX 20k shares available borrow free 49 percent at

0 · Reply

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 14, 2025, 7:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Apr 30, 2025, 7:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 10, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 2, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Mar 31, 2025, 4:18 AM EDT - 3 months ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 25, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 13, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 4, 2025, 7:30 AM EST - 4 months ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Feb 27, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 25, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 4, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Jan 23, 2025, 8:30 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 5:30 AM EST - 6 months ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 6, 2025, 8:30 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Dec 20, 2024, 9:20 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 19, 2024, 8:00 AM EST - 7 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 18, 2024, 8:18 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Oct 31, 2024, 4:05 PM EDT - 9 months ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Sep 9, 2024, 8:30 AM EDT - 11 months ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 5:00 AM EDT - 1 year ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

May 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Mar 14, 2024, 12:57 PM EDT - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 7, 2024, 4:05 PM EST - 1 year ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Feb 14, 2024, 9:00 AM EST - 1 year ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Dec 13, 2023, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Nov 9, 2023, 10:51 AM EST - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 5:46 PM EST - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 3, 2023, 8:41 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Oct 24, 2023, 9:32 AM EDT - 1 year ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 8:28 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Aug 7, 2023, 1:24 AM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 4:45 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

May 24, 2023, 8:15 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 12, 2023, 4:43 PM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

May 8, 2023, 5:00 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 2, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

Mar 21, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Mar 9, 2023, 2:27 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 5:08 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Feb 22, 2023, 8:39 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Dec 13, 2022, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Nov 10, 2022, 2:38 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

TestacularTommy Jul. 17 at 12:06 AM

0 · Reply

Trust121 Jul. 14 at 6:45 PM

$QNRX Nice uptrend, steady

0 · Reply

Thestocktraderhubzee Jul. 9 at 9:30 AM

1 · Reply

StayPresent Jul. 8 at 2:02 AM

$QNRX pos

1 · Reply

TwongStocks Jul. 7 at 10:20 PM

0 · Reply

GreenResearchers Jul. 7 at 4:01 AM

0 · Reply

GreenResearchers Jul. 5 at 8:31 PM

0 · Reply

rockytoday Jul. 3 at 4:39 PM

$QNRX buy the dip

0 · Reply

magic2007 Jul. 3 at 2:23 PM

$QNRX So I invested 7k way back, and now I see I have 14 shares. Wow, I guess I ride it out..

1 · Reply

Kevin73ca Jun. 26 at 5:34 PM

$QNRX 20k shares available borrow free 49 percent at

0 · Reply

Kevin73ca Jun. 26 at 3:09 PM

$CYN watch $QNRX this is also next

0 · Reply

prismmarketview Jun. 26 at 2:37 PM

$QNRX “It’s not just a skin disease—it can be life-threatening.” Quoin Pharmaceuticals (Nasdaq: QNRX) spotlights the urgent pediatric need in Netherton Syndrome in a powerful new NETHERTON NOW episode featuring leading dermatologist Prof. Jemima Mellerio. Don’t miss this expert perspective on the fight to bring treatments to children who need them mosthttps://prismmarketview.com/quoin-pharmaceuticals-highlights-urgent-pediatric-need-in-netherton-syndrome-with-new-expert-video/

0 · Reply

StayPresent Jun. 25 at 11:18 PM

$QNRX should be OTC. China dog💩

1 · Reply